XTNT (Xtant Medical Holdings, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by XTNT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | ABHINAV JAIN | Director | A | — | — |
| 2026-08-18 | Scott C Neils | CFO and Assistant Secretary | MIXED | — | — |
| 2026-08-18 | Jonn R. Beeson | Director | A | — | — |
| 2026-08-18 | Sean E Browne | President and CEO | MIXED | — | — |
| 2026-08-18 | Mark A. Schallenberger | Chief Operating Officer | MIXED | — | — |
| 2026-08-18 | JOHN K BAKEWELL | Director | A | — | — |
| 2026-08-18 | Stavros G. Vizirgianakis | Director | A | — | — |
| 2026-08-18 | Tyler Lipschultz | Director | A | — | — |
| 2026-02-18 | Mark A. Schallenberger | Chief Operating Officer | F | — | — |
| 2026-01-16 | Scott C Neils | CFO and Assistant Secretary | F | — | — |
| 2025-11-18 | Tyler Lipschultz | Director | A | — | — |
| 2025-11-18 | JOHN K BAKEWELL | Director | A | — | — |
| 2025-11-18 | Stavros G. Vizirgianakis | Director | A | — | — |
| 2025-11-18 | Scott C Neils | CFO and Assistant Secretary | A | — | — |
| 2025-11-18 | Jonn R. Beeson | Director | A | — | — |
| 2025-11-18 | JOHN K BAKEWELL | Director | A | — | — |
| 2025-11-18 | ABHINAV JAIN | Director | A | — | — |
| 2025-11-18 | Sean E Browne | President and CEO | A | — | — |
| 2025-11-18 | Mark A. Schallenberger | Chief Operating Officer | A | — | — |
| 2025-08-19 | Sean E Browne | President and CEO | F | — | — |
| 2025-08-19 | Scott C Neils | CFO | F | — | — |
| 2025-04-14 | Orbimed ROF II LLC | 10%+ Owner | Sell | — | — |
| 2025-01-17 | Scott C Neils | Chief Financial Officer | F | — | — |
| 2025-01-17 | Mark A. Schallenberger | Chief Operations Officer | A | — | — |
| 2024-10-16 | Sean E Browne | President and CEO | F | — | — |
| 2024-08-19 | JOHN K BAKEWELL | Director | A | — | — |
| 2024-08-19 | Kevin D Brandt | Chief Commercial Officer | F | — | — |
| 2024-08-19 | Scott C Neils | Chief Financial Officer | F | — | — |
| 2024-08-19 | Sean E Browne | President and CEO | F | — | — |
| 2024-08-19 | Robert McNamara | Director | A | — | — |
| 2024-08-19 | Jonn R. Beeson | Director | A | — | — |
| 2024-08-19 | LORI D MITCHELL-KELLER | Director | A | — | — |
| 2024-08-19 | Stavros G. Vizirgianakis | Director | A | — | — |
| 2024-04-05 | Scott C Neils | Chief Financial Officer | A | — | — |
| 2024-04-05 | Sean E Browne | President and CEO | A | — | — |
| 2024-04-05 | Kevin D Brandt | Chief Commercial Officer | A | — | — |
| 2024-04-05 | Mark A. Schallenberger | Chief Operations Officer | A | — | — |
| 2024-02-16 | Sean E Browne | President and CEO | F | — | — |
| 2024-01-18 | Scott C Neils | Chief Financial Officer | F | — | — |
| 2023-11-17 | Kevin D Brandt | Chief Commercial Officer | Buy | — | — |
| 2023-10-17 | Sean E Browne | President and CEO | F | — | — |
| 2023-08-17 | Robert McNamara | Director | A | — | — |
| 2023-08-17 | Sean E Browne | President and CEO | A | — | — |
| 2023-08-17 | Scott C Neils | Chief Financial Officer | MIXED | — | — |
| 2023-08-17 | JOHN K BAKEWELL | Director | A | — | — |
| 2023-08-17 | LORI D MITCHELL-KELLER | Director | A | — | — |
| 2023-08-17 | Mark A. Schallenberger | Chief Operations Officer | A | — | — |
| 2023-08-17 | Stavros G. Vizirgianakis | Director | A | — | — |
| 2023-08-17 | Jonn R. Beeson | Director | A | — | — |
| 2023-08-17 | Kevin D Brandt | Chief Commercial Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 17,325,033 | — |
| — | Director | 17,325,033 | — |
| — | Director | 7,838,845 | — |
| — | President and CEO | 3,125,274 | — |
| — | Director | 1,748,408 | — |
| — | CFO and Assistant Secretary | 1,243,381 | — |
| — | Director | 1,129,633 | — |
| — | Chief Operating Officer | 1,113,157 | — |
| — | Chief Commercial Officer | 943,736 | — |
| — | Director | 754,151 | — |
| — | Director | 448,546 | — |
| — | Director | 373,745 | — |
| — | Director | 373,745 | — |
| — | Director | 353,124 | — |
| — | Vice President, Finance & CFO | 285,331 | — |
| — | Director | 215,415 | — |
| — | EVP & Chief Scientific Officer | 141,672 | — |
| — | Director | 42,377 | — |
| — | 10%+ Owner | 42,169 | — |
| — | Director | 28,220 | — |
| — | 10%+ Owner | 21,793 | — |
| — | Director | 21,793 | — |
| — | 10%+ Owner | 21,793 | — |
| — | Interim CEO | 20,833 | — |
| — | 10%+ Owner | 20,080 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XTNT quote page; the site-wide leaderboard is on the insider transactions hub.